For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
This report studies the Iron Chelation Drug market. The rationale behind using Iron chelation therapy is removing the increased iron burden specifically labile cell iron (LCI) to minimize production of reactive oxygen species (ROS) thereby decreasing cellular and organ damage. Patients most likely to benefit from chelation therapy include those with low or intermediate-1 IPSS risk MDS who have a long-life expectancy and are anticipated to receive more than 20 red blood cell transfusions and/or whose serum ferritin level is >1000 µg/L. Chelation therapy efficacy can be monitored by monitoring trends and levels of serum ferritin.
Scope of the Report:
North America is the largest consumption region of Iron Chelation Drug, with a consumption value market share nearly 31.03% in 2016. Europe is the second largest consumption region of Iron Chelation Drug, enjoying consumption value market share nearly 25.30% in 2016. Apotex, Cipla and other company are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The worldwide market for Iron Chelation Drug is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Iron Chelation Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- Apotex Inc. (Canada)
- Cipla (India)
- Novartis (Switzerland)
- Sun Pharma (India)
- Natco Pharma (India)
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Deferoxamine
- Deferiprone
- Deferasirox
Market Segment by Applications, can be divided into
- Transfusional Iron Overload
- NTDT Caused Iron Overload
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Iron Chelation Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Iron Chelation Drug, with price, sales, revenue and global market share of Iron Chelation Drug in 2017 and 2018.
Chapter 3, the Iron Chelation Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Iron Chelation Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Iron Chelation Drug market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Iron Chelation Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.